NextCure (NASDAQ:NXTC) Trading Down 3.1% – What’s Next?

NextCure, Inc. (NASDAQ:NXTC)’s stock price fell 3.1% on Friday . The company traded as low as $6.02 and last traded at $6.20. 11,495 shares were traded during mid-day trading, a decline of 71% from the average session volume of 40,293 shares. The stock had previously closed at $6.40.

Analysts Set New Price Targets

A number of brokerages recently weighed in on NXTC. Weiss Ratings reiterated a “sell (d-)” rating on shares of NextCure in a research report on Monday, April 27th. Zacks Research downgraded shares of NextCure from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 6th. Three research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $23.00.

NextCure Stock Performance

The stock has a market capitalization of $22.38 million, a price-to-earnings ratio of -0.36 and a beta of 1.43. The firm’s fifty day simple moving average is $10.04 and its 200 day simple moving average is $11.47.

NextCure (NASDAQ:NXTC) last announced its earnings results on Thursday, May 7th. The company reported ($1.87) EPS for the quarter, topping the consensus estimate of ($2.10) by $0.23. Analysts forecast that NextCure, Inc. will post -7.91 earnings per share for the current year.

Institutional Trading of NextCure

Several hedge funds have recently bought and sold shares of NXTC. Cable Car Capital LP raised its holdings in NextCure by 13.1% during the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock worth $349,000 after buying an additional 88,040 shares during the period. Geode Capital Management LLC raised its holdings in NextCure by 18.6% during the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after buying an additional 3,636 shares during the period. Renaissance Technologies LLC raised its holdings in NextCure by 18.7% during the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after buying an additional 5,300 shares during the period. Exome Asset Management LLC acquired a new stake in NextCure during the 4th quarter worth approximately $2,341,000. Finally, AWM Investment Company Inc. acquired a new stake in NextCure during the 4th quarter worth approximately $1,665,000. 42.65% of the stock is currently owned by institutional investors and hedge funds.

NextCure Company Profile

NextCure, Inc is a clinical?stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large?scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.